文献速递关节外科

商业保险支付方全关节置换术覆盖政策证据级别分析

What is the Level of Evidence Substantiating Commercial Payers' Coverage Policies for Total Joint Arthroplasty?
PubMed 文献 · J Arthroplasty · 2021-03-22

该研究审查了美国四家商业保险公司全关节置换术(TJA)覆盖政策的参考文献,发现仅14.2%为I级或II级证据,41.2%适用于TJA候选患者,9.9%讨论非手术治疗的成功的。结论认为支付方引用的多数文献证据级别较低且不适用于TJA候选患者,缺乏高质量证据反映严重症状性骨关节炎手术与非手术结局研究难以开展。

要点

  • 支付方覆盖政策引用的文献中仅14.2%为I级或II级证据。
  • 41.2%的文献适用于TJA候选患者,9.9%讨论非手术治疗的成功的。
  • 多数引用证据级别低且不适用,各支付方之间相对一致。

核心结论

  • 商业支付方引用的多数文献科学证据级别较低,且不适用于考虑TJA候选的患者,各支付方情况相对一致。

研究设计与样本

  • 审查美国四家商业保险公司覆盖政策的参考文献,评估文献类型、证据级别、对TJA人群的适用性及非手术治疗的成功的。

主要发现

  • 共审查282篇文献,45.8%为主要期刊文章,14.2%为I级或II级证据。
  • 41.2%的文献适用于TJA候选患者,9.9%讨论非手术治疗的成功的。

临床怎么用

  • 临床医生应了解支付方覆盖政策所依据的证据级别较低,在沟通时可指出高质量证据的缺乏。

局限性

  • 原文未报告审查的具体保险公司的名称,也未报告文献筛选和质量评价的具体方法学细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of total joint arthroplasty (TJA) in the United States has drawn the attention of health care stakeholders. The payers have also used a variety of strategies to regulate the medical necessity of these procedures. The purpose of this study was to examine the level of evidence of the coverage policies being used by commercial payers in the United States. METHODS: The references of the coverage policies of four commercial insurance companies were reviewed for type of document, level of evidence, applicability to a TJA population, and success of nonoperative treatment in patients with severe degenerative joint disease. RESULTS: 282 documents were reviewed. 45.8% were primary journal articles, 14.2% were level I or II, 41.2% were applicable to patients who were candidates for TJA, and 9.9% discussed the success of nonoperative treatment in patients who would be candidates for TJA. CONCLUSION: Most of the references cited by commercial payers are of a lower level of scientific evidence and not applicable to patients considered to be candidates for TJA. This is relatively uniform across the reviewed payers. The dearth of high-quality literature cited by commercial payers reflects the lack of evidence and difficulty in conducting high level studies on the outcomes of nonoperative versus operative treatment for patients with severe, symptomatic osteoarthritis. Patients, surgeons, and payers would all benefit from such studies and we encourage professional societies to strive toward that end through multicenter collaboration.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Austin MS, Ashley BS, Bedard NA, et al. What is the Level of Evidence Substantiating Commercial Payers' Coverage Policies for Total Joint Arthroplasty? J Arthroplasty. 2021. PMID: 33867209. doi:10.1016/j.arth.2021.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。